KP Tissue Inc. (TSE:KPT)
TSX:KPT
Top Page
KP Tissue
(TSX:KPT)
Select Model
Select Model
Rating:62Neutral
Price Target:
C$11.00
▲(2.42% Upside)
Action:ReiteratedDate:12/30/25
The score is primarily held back by inconsistent profitability and uneven/unclear latest cash flow in the provided statements, despite a strong low-leverage balance sheet. Offsetting this, technicals show a clear uptrend with positive momentum, and the earnings call indicated strong recent operating performance and credible long-term capacity expansion plans. Valuation is mixed, with a high dividend yield but a relatively high P/E.
Positive Factors
Revenue Growth
Achieving record revenue reflects strong market demand and effective sales strategies, indicating a robust growth trajectory for the company.
Negative Factors
Profitability Challenges
Ongoing profitability challenges can hinder reinvestment in growth initiatives and impact long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Achieving record revenue reflects strong market demand and effective sales strategies, indicating a robust growth trajectory for the company.
Read all positive factors
KP Tissue (KPT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$107.64M
Dividend Yield7.04%
Average Volume (3M)17.75K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue GrowthN/A
EPS Growth-39.19%
CountryCA
Employees2,700
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.60
Shares Outstanding10,022,337
10 Day Avg. Volume14,081
30 Day Avg. Volume17,752
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.00Price Target Upside2.42% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)0.74
Revenue Forecast (FY)C$2.30B
KP Tissue Business Overview & Revenue Model
Company Description
KP Tissue Inc., through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through two segments, Consumer and Away-From-Home. ...
How the Company Makes Money
KP Tissue makes money through its equity interest in Kruger Products L.P., which generates revenue by manufacturing and distributing tissue products across North America. The company earns money by selling these products to major retailers, wholes...
KP Tissue Earnings Call Summary
Earnings Call Date:Feb 18, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: double-digit adjusted EBITDA growth, revenue gains, market-share expansion in Canada, a net income turnaround and improved liquidity and leverage. Challenges include modest sequential softness in revenue and EBITDA, rising operating and SG&A costs, pulp price volatility with potential upward pressure in 2026, and higher planned CapEx with possible short-term leverage increases tied to a new TAD project. On balance, the positive performance metrics and strategic progress outweigh the near-term headwinds.Positive Updates
Adjusted EBITDA Growth and Margin Improvement
Q4 adjusted EBITDA of $84.2M, up 26% year-over-year; adjusted EBITDA margin improved to 15.0% from 12.4% a year ago; run-rate above $80M for a second consecutive quarter.
Negative Updates
Sequential Revenue and EBITDA Softness
Q4 revenue down slightly vs Q3 by $1M or -0.2% sequentially; U.S. revenue sequentially down $6M or -2.3%. Adjusted EBITDA declined $1.5M QoQ (-1.8%).
Read all updates
Q4-2025 Updates
Positive
Negative
Adjusted EBITDA Growth and Margin Improvement
Q4 adjusted EBITDA of $84.2M, up 26% year-over-year; adjusted EBITDA margin improved to 15.0% from 12.4% a year ago; run-rate above $80M for a second consecutive quarter.
Read all positive updates
Company Guidance
Management guided Q1 2026 adjusted EBITDA to be in a similar range to Q4 2025 (Q4 adjusted EBITDA $84.2M; run rate above $80M for a second consecutive quarter) with consolidated adjusted EBITDA margin ~15% (consumer margin 16.5%, AFH margin 11%). They raised 2026 CapEx to $100–$120M (FY2025 CapEx $78M; Q4 CapEx $33.4M), with base CapEx ~$50–70M, Line 11 spending $25–35M and a small amount of first‑year TAD project spend. The new converting line in Memphis is on track for early Q2 2026 start, a proposed Western U.S. TAD plant is slated to open in 2028 with a detailed announcement expected H1 2026, and financing could push leverage briefly above 4x (current leverage 3.1x; long‑term debt $1.741B; cash $196.1M; net debt reduced by $55.7M). Management will monitor pulp and other input costs (Q4 pulp QoQ range -6.6% to +3.3%; NBSK -7.3% YoY; BEK -5.3% YoY) and use its pricing model to respond as needed.KP Tissue Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 76.09M | 264.78M | 238.61M | 115.99M | 153.43M | 197.84M |
| Net Income | 4.43M | 2.43M | -4.94M | -10.25M | 1.24M | -1.95M |
Balance Sheet | ||||||
| Total Assets | 70.52M | 71.31M | 70.61M | 81.71M | 80.72M | 71.31M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.80M | 1.80M | 2.25M | 7.68M | 4.85M | 4.99M |
| Stockholders Equity | 68.72M | 69.52M | 68.36M | 74.03M | 75.87M | 66.33M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | 6.98M | 6.62M | 1.15M | -2.44M |
| Operating Cash Flow | 0.00 | 0.00 | 6.98M | 6.62M | 1.15M | -2.44M |
| Investing Cash Flow | 6.97M | 6.97M | 6.98M | 6.62M | 5.56M | 5.59M |
| Financing Cash Flow | -5.23M | -6.97M | -6.98M | -6.62M | -5.56M | -5.59M |
KP Tissue Technical Analysis
Positive
10.74
Price Trends
10.52
Positive
10.21
Positive
9.54
Positive
Market Momentum
0.07
Positive
51.01
Neutral
28.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KPT, the sentiment is Positive. The current price of 10.74 is below the 20-day moving average (MA) of 10.77, above the 50-day MA of 10.52, and above the 200-day MA of 9.54, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.01 is Neutral, neither overbought nor oversold. The STOCH value of 28.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KPT.
KP Tissue Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | C$413.84M | 11.92 | 15.74% | 6.34% | 8.87% | 10.15% | |
73 Outperform | C$413.84M | 11.45 | 15.23% | 6.57% | 8.87% | 10.15% | |
73 Outperform | C$853.92M | 6.68 | 16.98% | 5.99% | 6.57% | 8.61% | |
67 Neutral | C$238.23M | 7.36 | 8.23% | 4.71% | -2.11% | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | C$107.64M | ― | 5.63% | 7.04% | ― | -39.19% | |
61 Neutral | C$406.08M | 8.64 | 8.89% | 4.83% | 6.15% | -36.76% |
* Consumer Defensive Sector Average
TSE:KPT
KP Tissue
10.74
3.57
49.73%
TSE:ADW.A
Andrew Peller A NV
5.29
1.08
25.74%
TSE:CSW.A
Corby Spirit&Wine A
14.56
0.74
5.35%
TSE:CSW.B
Corby Spirit&Wn B NV
14.40
1.87
14.91%
TSE:HLF
High Liner Foods
14.35
-1.40
-8.87%
TSE:RSI
Rogers Sugar
6.66
1.71
34.57%
KP Tissue Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Kruger Products Secures $165 Million in Senior Unsecured Notes Offering
Positive
Dec 10, 2025
KP Tissue Inc. announced that Kruger Products Inc. has successfully closed a CDN $165 million offering of senior unsecured notes due in 2032. The proceeds from this offering will be used to repay existing borrowings and for general corporate purpo...
Private Placements and Financing
Kruger Products Inc. Announces $165 Million Senior Unsecured Notes Offering
Positive
Dec 4, 2025
KP Tissue Inc. announced that Kruger Products Inc. will issue and sell CDN $165 million in Senior Unsecured Notes due in 2032 through a private placement, with the offering expected to close on December 10, 2025. The proceeds from this offering wi...
Private Placements and Financing
Kruger Products Announces $165 Million Notes Offering to Enhance Credit Profile
Neutral
Nov 26, 2025
KP Tissue Inc. announced that Kruger Products Inc. plans to offer CAD $165 million in Senior Unsecured Notes through a private placement. The proceeds will be used to repay borrowings under Kruger Products SB Inc.’s senior credit facilities ...
Business Operations and StrategyFinancial Disclosures
KP Tissue Reports Q3 Growth and Announces New Facility
Positive
Nov 13, 2025
KP Tissue Inc. reported a 7.7% increase in revenue for Q3 2025, reaching $561.1 million, driven by higher sales volumes and favorable pricing. The company also announced plans to build a new TAD tissue facility by 2028 to support its growth in ult...
Business Operations and StrategyFinancial Disclosures
KP Tissue Reports Strong Q3 2025 Growth and Announces New Facility
Positive
Nov 13, 2025
KP Tissue Inc. reported a 7.7% increase in revenue to $561.1 million for Q3 2025, with Adjusted EBITDA rising by 30.4% to $85.7 million, driven by higher sales volumes and favorable pricing. Despite a decrease in net income due to foreign exchange...
Dividends
KP Tissue Announces Quarterly Dividend and Reinvestment Plan
Neutral
Nov 13, 2025
KP Tissue Inc. announced a quarterly dividend of $0.18 per common share, payable on January 15, 2026, to shareholders of record as of December 31, 2025. This dividend declaration is linked to a corresponding distribution by Kruger Products Inc., i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.